Generating evidence for Health Technology Assessment - Flyer
Agenda
Early dialogue with HTA agencies
Applying Real-World Data in HTA – Why one size does not fit all
Biometrical issues in the framework of benefit assessment in Germany
Meeting local HTA requirements – challenges for the Pharma statistician
Deriving minimally important difference for PRO data
Designing better observational studies: The role of the pharmaceutical statistician
Analytical Strategy, Credibility and Rigor of Evidence
Subgroups for regulatory vs HTA – methods and perspectives